See more : Zedcor Inc. (CRFQF) Income Statement Analysis – Financial Results
Complete financial analysis of Pharvaris N.V. (PHVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharvaris N.V., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- I.B.I Investment House Ltd. (IBI.TA) Income Statement Analysis – Financial Results
- Datamatics Global Services Limited (DATAMATICS.BO) Income Statement Analysis – Financial Results
- AnalytixInsight Inc. (ALY.V) Income Statement Analysis – Financial Results
- Wonderful Hi-tech Co., Ltd. (6190.TWO) Income Statement Analysis – Financial Results
- Cosmo Ferrites Limited (COSMOFE.BO) Income Statement Analysis – Financial Results
Pharvaris N.V. (PHVS)
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 252.27K | 150.19K | 80.46K | 0.00 | 547.41 | 0.00 |
| Gross Profit | -252.27K | -150.19K | -80.46K | 0.00 | -547.41 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 65.58M | 57.38M | 35.79M | 19.51M | 5.68M | 3.65M |
| General & Administrative | 31.14M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Selling & Marketing | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.34M | 29.34M | 18.35M | 5.50M | 2.33M | 668.12K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Cost & Expenses | 96.91M | 86.71M | 54.14M | 25.01M | 8.01M | 4.31M |
| Interest Income | 0.00 | 16.11 | 267.51 | 92.47 | 4.38 | 0.00 |
| Interest Expense | 20.06K | 16.11K | 278.18K | 92.47K | 0.00 | 0.00 |
| Depreciation & Amortization | 59.78K | 150.19K | 80.46K | 7.40K | 547.41 | 4.31M |
| EBITDA | -96.85M | -86.58M | -54.06M | -25.01M | -8.01M | -4.31M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -96.91M | -86.74M | -65.90M | -25.01M | -7.99M | -4.31M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.91M | 11.08M | 11.48M | -1.06M | -16.88K | -380.00 |
| Income Before Tax | -99.83M | -75.65M | -42.66M | -26.07M | -8.03M | -4.31M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.05M | 679.09K | 70.12K | -83.25K | 16.88K | 380.00 |
| Net Income | -100.88M | -76.33M | -42.73M | -25.99M | -8.04M | -4.31M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| EPS Diluted | -2.63 | -2.27 | -1.41 | -0.85 | -1.66 | -0.14 |
| Weighted Avg Shares Out | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
| Weighted Avg Shares Out (Dil) | 38.39M | 33.59M | 30.41M | 30.52M | 4.85M | 31.84M |
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September...
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming...
Pharvaris to Host Virtual Investor Event on October 23, 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to...
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral...
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the planned initiation of CHAPTER-3, the pivotal Phase...
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated profile of deucrictibant as a prophylactic...
Pharvaris Presents Data at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced a summary of data being presented at the...
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation...
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
ZUG, Switzerland, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the financial results for the second quarter ended...
Source: https://incomestatements.info
Category: Stock Reports